{"id":"bnt162b2-pfizer","safety":{"commonSideEffects":[{"rate":"70–90","effect":"Injection site pain"},{"rate":"60–70","effect":"Fatigue"},{"rate":"50–60","effect":"Headache"},{"rate":"40–60","effect":"Myalgia"},{"rate":"15–40","effect":"Fever"},{"rate":"30–35","effect":"Chills"},{"rate":"20–30","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4650429","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine delivers lipid nanoparticle-encapsulated messenger RNA encoding the full-length, prefusion-stabilized spike protein of SARS-CoV-2. Upon intramuscular injection, the mRNA is translated by host cells to produce spike protein antigen, which activates both CD8+ T-cell and B-cell mediated immunity. This dual immune response generates neutralizing antibodies and cellular immunity against the virus.","oneSentence":"BNT162b2 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:47:18.850Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 6 months of age and older"},{"name":"Primary series and booster immunization against SARS-CoV-2"}]},"trialDetails":[{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT05876377","phase":"","title":"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome","enrollment":1},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT07390968","phase":"PHASE2","title":"Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-09-01","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":56},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT04780659","phase":"PHASE4","title":"COVID-19 Vaccination of Immunodeficient Persons (COVAXID)","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2021-02-23","conditions":"Covid19","enrollment":539},{"nctId":"NCT06703190","phase":"","title":"Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-11-25","conditions":"COVID-19","enrollment":1},{"nctId":"NCT06742281","phase":"PHASE2","title":"A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"CyanVac LLC","startDate":"2024-12-05","conditions":"COVID-19","enrollment":432},{"nctId":"NCT06672055","phase":"PHASE2","title":"A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxart","startDate":"2024-10-08","conditions":"SARS-CoV2, COVID-19","enrollment":10400},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT05571735","phase":"","title":"Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-04-15","conditions":"Covid-19 Pandemics, Tuberculosis","enrollment":133},{"nctId":"NCT04761822","phase":"PHASE2","title":"COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-07","conditions":"SARS-CoV Infection, COVID-19, Allergic Reaction","enrollment":746},{"nctId":"NCT04932863","phase":"","title":"BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment","status":"COMPLETED","sponsor":"Ente Ospedaliero Ospedali Galliera","startDate":"2021-03-15","conditions":"Neoplasms, Cancer, Treatment-Related","enrollment":300},{"nctId":"NCT04969263","phase":"PHASE2","title":"COVID-19 Protection After Transplant Pilot Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-10","conditions":"Kidney Transplant Recipients","enrollment":81},{"nctId":"NCT04848584","phase":"","title":"Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-15","conditions":"COVID-19","enrollment":1},{"nctId":"NCT05321407","phase":"","title":"COVID-19 Vaccine Responses in PIDD Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2021-09-30","conditions":"X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency","enrollment":100},{"nctId":"NCT05525208","phase":"PHASE2","title":"Booster Study of COVID-19 Protein Subunit Recombinant Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-09-01","conditions":"COVID-19","enrollment":696},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT04894435","phase":"PHASE2","title":"Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2021-05-20","conditions":"COVID-19","enrollment":669},{"nctId":"NCT05022329","phase":"PHASE2, PHASE3","title":"COVID-19 Vaccine Boosters in Patients With CKD","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-09-30","conditions":"Chronic Kidney Diseases, COVID-19","enrollment":273},{"nctId":"NCT05228730","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).","status":"TERMINATED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":13},{"nctId":"NCT05047718","phase":"PHASE4","title":"Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2021-10-05","conditions":"Covid19","enrollment":54},{"nctId":"NCT05697705","phase":"","title":"Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-22","conditions":"COVID-19","enrollment":188814085},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT06597370","phase":"","title":"Immunogenicity Induced by COVID-19 Vaccines in Mexican Population","status":"COMPLETED","sponsor":"National Polytechnic Institute, Mexico","startDate":"2021-09-01","conditions":"COVID-19 Vaccine","enrollment":80},{"nctId":"NCT05858450","phase":"","title":"This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-05","conditions":"Influenza, Human, COVID-19","enrollment":3442996},{"nctId":"NCT04922944","phase":"","title":"Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients","status":"COMPLETED","sponsor":"Huntington Memorial Hospital","startDate":"2021-03-08","conditions":"Covid19, Vaccine Reaction","enrollment":167},{"nctId":"NCT06587503","phase":"PHASE4","title":"Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses","status":"NOT_YET_RECRUITING","sponsor":"University of Birmingham","startDate":"2024-10","conditions":"Ebola Virus Disease, COVID-19","enrollment":72},{"nctId":"NCT05765578","phase":"","title":"An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-08","conditions":"COVID-19","enrollment":1713},{"nctId":"NCT05515042","phase":"PHASE2","title":"Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2022-07-25","conditions":"COVID-19","enrollment":694},{"nctId":"NCT06429020","phase":"","title":"Sonography for COVID-19 Vaccines Related Reactive Lymphadenopathy","status":"COMPLETED","sponsor":"Chimei Medical Center","startDate":"2023-01-01","conditions":"Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population","enrollment":1089},{"nctId":"NCT05977127","phase":"PHASE2","title":"Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2023-09-26","conditions":"Vaccination; Infection, COVID-19","enrollment":48},{"nctId":"NCT04969250","phase":"PHASE4","title":"Vaccination for Recovered Inpatients With COVID-19 (VATICO)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-25","conditions":"Covid19","enrollment":66},{"nctId":"NCT05406908","phase":"PHASE4","title":"Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2022-06-15","conditions":"Bullous Dermatoses, Psoriasis, COVID-19 Vaccines","enrollment":109},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05543356","phase":"PHASE3","title":"COVID-19 Fourth Dose Study in Australia","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05020145","phase":"","title":"COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-25","conditions":"Immunocompromised, Immunosuppressed, Covid-19","enrollment":1277747},{"nctId":"NCT05343871","phase":"PHASE4","title":"Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2022-07-05","conditions":"COVID-19","enrollment":2354},{"nctId":"NCT04805125","phase":"PHASE3","title":"Immunocompromised Swiss Cohorts Based Trial Platform","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-19","conditions":"Immunocompromised Patients","enrollment":610},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT05403307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2022-06-08","conditions":"COVID-19","enrollment":757},{"nctId":"NCT04742842","phase":"PHASE1","title":"The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2021-06-21","conditions":"SARS-CoV2 COVID-19","enrollment":68},{"nctId":"NCT04977479","phase":"PHASE2","title":"The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-08","conditions":"Systemic Allergic Reaction","enrollment":20},{"nctId":"NCT04775069","phase":"PHASE4","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2021-05-21","conditions":"Chronic Liver Disease","enrollment":232},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT05517642","phase":"PHASE3","title":"IH Convidecia as Second Booster Dose Against Breakthrough Infections","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2022-09-20","conditions":"COVID-19","enrollment":540},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05405283","phase":"PHASE3","title":"Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-08","conditions":"COVID-19 Vaccines","enrollment":189},{"nctId":"NCT05749926","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-05-16","conditions":"Vaccine Reaction, COVID-19","enrollment":248},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":"Covid19, SARS-CoV2 Infection","enrollment":43},{"nctId":"NCT05516459","phase":"","title":"Prospective Monitoring of BNT162b2 Second Vaccination Booster Effects in Health Care Workers (HCW)","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2022-01-06","conditions":"Coronavirus Infections","enrollment":635},{"nctId":"NCT05490108","phase":"PHASE1, PHASE2","title":"Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.","status":"UNKNOWN","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2022-06-02","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":60},{"nctId":"NCT05175742","phase":"PHASE2","title":"PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.","status":"COMPLETED","sponsor":"Providence Therapeutics Holdings Inc.","startDate":"2021-08-17","conditions":"Covid19 Vaccine","enrollment":565},{"nctId":"NCT04852861","phase":"PHASE4","title":"COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine","status":"COMPLETED","sponsor":"Sciensano","startDate":"2021-05-10","conditions":"Covid19","enrollment":145},{"nctId":"NCT05305573","phase":"PHASE2","title":"Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2022-03-25","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":26},{"nctId":"NCT05175950","phase":"PHASE2","title":"Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2022-01-24","conditions":"COVID-19 (Healthy Volunteers)","enrollment":770},{"nctId":"NCT05168709","phase":"PHASE4","title":"Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-01-20","conditions":"COVID-19, Vaccine Reaction, Immunization; Infection","enrollment":51},{"nctId":"NCT05686161","phase":"PHASE3","title":"mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2022-10-19","conditions":"Immunogenicity, Safety, Efficacy","enrollment":600},{"nctId":"NCT05668065","phase":"PHASE3","title":"Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines","status":"COMPLETED","sponsor":"Institut Pasteur de Tunis","startDate":"2021-11-22","conditions":"COVID-19","enrollment":199},{"nctId":"NCT05076227","phase":"","title":"Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity","status":"COMPLETED","sponsor":"Serge Thal","startDate":"2021-01-30","conditions":"SARS-CoV2 Infection, Immunisation Reaction, Antibody Hypersensitivity","enrollment":1206},{"nctId":"NCT05465863","phase":"NA","title":"Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2021-09-01","conditions":"Chronic Kidney Disease 5D, Chronic Kidney Disease 5T","enrollment":101},{"nctId":"NCT05124171","phase":"PHASE3","title":"Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-08","conditions":"COVID-19, Vaccine Reaction","enrollment":247},{"nctId":"NCT05049226","phase":"PHASE2","title":"Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2021-09-24","conditions":"COVID-19 Infection, COVID-19 VACCINE","enrollment":1250},{"nctId":"NCT04951323","phase":"PHASE3","title":"Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)","status":"UNKNOWN","sponsor":"University of Liege","startDate":"2021-03-22","conditions":"Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms","enrollment":50},{"nctId":"NCT05308680","phase":"","title":"Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2022-01-06","conditions":"Myocardial Injury, Vaccine Adverse Reaction, COVID-19","enrollment":336},{"nctId":"NCT05329064","phase":"PHASE4","title":"Determining Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children","status":"UNKNOWN","sponsor":"KK Women's and Children's Hospital","startDate":"2022-03-24","conditions":"Vaccine Reaction, COVID-19, Children, Only","enrollment":150},{"nctId":"NCT04743388","phase":"","title":"Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System","status":"UNKNOWN","sponsor":"National and Kapodistrian University of Athens","startDate":"2021-01-04","conditions":"COVID-19, Healthy Volunteers, Chronic Disease","enrollment":600},{"nctId":"NCT05315856","phase":"","title":"Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2021-03-01","conditions":"COVID-19 Vaccination, Inflammation, Vaccine Immune Response","enrollment":120},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000},{"nctId":"NCT05279365","phase":"PHASE2, PHASE3","title":"PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS","status":"UNKNOWN","sponsor":"DHR Health Institute for Research and Development","startDate":"2021-07-30","conditions":"SARS CoV 2 Infection, COVID-19","enrollment":1000},{"nctId":"NCT04824651","phase":"","title":"Covid-19 Vaccine Cohort in Specific Populations","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-03-25","conditions":"Immune Deficiency","enrollment":6920},{"nctId":"NCT05225285","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents","status":"UNKNOWN","sponsor":"Federal University of Espirito Santo","startDate":"2022-01-21","conditions":"COVID-19","enrollment":1120},{"nctId":"NCT05157230","phase":"NA","title":"Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination","status":"COMPLETED","sponsor":"Bursa Yuksek Ihtisas Training and Research Hospital","startDate":"2021-09-01","conditions":"Vaccines, Adverse Effects, Injection Site Reaction","enrollment":401},{"nctId":"NCT05178264","phase":"","title":"Transverse Myelitis Related to SARS-CoV-2 Vaccines","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2021-12-10","conditions":"Vaccine Adverse Reaction","enrollment":580},{"nctId":"NCT05145348","phase":"","title":"Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2021-02-03","conditions":"Down Syndrome, SARS-CoV-2 Vaccination","enrollment":640},{"nctId":"NCT05113472","phase":"","title":"Adverse Reactions Following COVID-19 Vaccination Among Ecuadorian Healthcare Workers","status":"COMPLETED","sponsor":"Respiralab","startDate":"2021-03-01","conditions":"Adverse Drug Event","enrollment":1291},{"nctId":"NCT04993560","phase":"","title":"Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-07-18","conditions":"SARS-CoV 2 Infection, Covid19","enrollment":305},{"nctId":"NCT04961229","phase":"PHASE4","title":"Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response","status":"UNKNOWN","sponsor":"dafna yahav","startDate":"2021-10","conditions":"COVID-19 Acute Respiratory Distress Syndrome, Immunosuppression","enrollment":504},{"nctId":"NCT04900467","phase":"NA","title":"Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-28","conditions":"Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose","enrollment":418},{"nctId":"NCT04865900","phase":"","title":"Prevalence of Perimyocarditis After Covid-19 Vaccine","status":"UNKNOWN","sponsor":"Hillel Yaffe Medical Center","startDate":"2021-03-09","conditions":"Perimyocarditis, Covid19","enrollment":500},{"nctId":"NCT04842305","phase":"","title":"Mucosal Immunity in Terms of SARS-CoV-2 Antibodies in Saliva After COVID-19 Infection and Vaccination","status":"UNKNOWN","sponsor":"Lenanrt Friis-Hansen","startDate":"2021-04","conditions":"Covid19","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":644,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BNT162b2 (Pfizer)","genericName":"BNT162b2 (Pfizer)","companyName":"Federal University of Espirito Santo","companyId":"federal-university-of-espirito-santo","modality":"Biologic","firstApprovalDate":"","aiSummary":"BNT162b2 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection. Used for Prevention of COVID-19 in individuals 6 months of age and older, Primary series and booster immunization against SARS-CoV-2.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}